NRC Health stock
NRCNASDAQHealthcareISIN US6373722023
59Score 59 out of 100, Neutral
Price and trend
82 / 100
Price history
+80% in one yearThe chart shows daily closes over 13 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 39% above it.
Since April 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 76).
The price is at its 52-week high. Largest decline in 13 years: 86% (January 2020 to April 2025).
Chart figures for advanced users
- SMA 50$21.89
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$19.35
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)76
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$12.03
- The lowest closing price of the last twelve months.
- Resistance$27.07
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- NRC Health belongs to the Medical (Healthcare Information Services) industry (United States) and, with a market value of $570.01M, is number 20 of 25 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $137.39M (down 4% year on year) and earnings of $11.6M (down 53.2%).
- MEQIRI Score 59 out of 100 (Neutral): rank 288 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 286% of earnings over the last 12 months.Fundamentals 89
- Share buybacksShare count down 11% since 2020.Capital allocation 76
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 89
Weaknesses
- Earnings per share fallingDown 18.9% a year since 2020.Growth 17
- Margin fallingOperating margin 16.4%, average of the prior years 30.7% (to 2024).Profitability 57
- Volatile share priceVolatility 58% a year over the last 12 months.Stability 24
Its standout strengths are momentum and fundamentals, while stability and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
What lowers it
- solid fundamentals
- low growth grade (crashed less often in the backtest)
- price near its 52-week high
Valuation
Valuation signal
OvervaluedA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 3.4% on the twelve months before. Revenue has grown solidly since 2006, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 56%, operating 16%, net 8%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 2 Feb 2027in 82 days
- Last reported
- 27 Oct 2026EPS reported $0.21 (expected $0.18)above expectations
Analyst estimates
- Earnings per share
- $1.37+55.7%
- Revenue
- $165M+39.5%
- Earnings per share
- $1.110.0%
- Revenue
- $127M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +4.5%NRC Health confirms prior expectations, with margin expansion expected in the second half and a smaller headwind from the accounting change in Q3 and Q4.
“This accounting change had a pronounced revenue impact in the second quarter and we expect to see a smaller headwind in Q3 and Q4.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 27 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Harrison Shane RPurchase
17 Feb 2026, EVP & Chief Financial Officer
- Shares
- 8,000
- Price
- $12.27
- Value
- $98,162
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at NRC Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 59
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next larger and next smaller companies by market value
- HealthStreamHSTM $883.61M62
- PhreesiaPHR $795.13M55
- SOPHiA GENETICSSOPH $635.9M47
- RaySearch LaboratoriesRAY-B.ST $587.54M66
- Evolent HealthEVH $561.28M45
- CarlsmedCARL $507.83M46
- GPIGPI.MI $480.24M44
- ClaritevCTEV $478.09M42
ETFs that hold NRC Health
Held by 5 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| WisdomTree US High Dividend UCITS ETF AccWTD9 | 0.04% | 0.29% | €182.46M |
| WisdomTree US Equity Income UCITS ETF EUR Hedged AccWTDY | 0.04% | 0.35% | €204.34M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Show 1 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Oct 2023)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.